Susquehanna International Group’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,942
| Closed | -$128K | – | 13649 |
|
|
2023
Q1 | $128K | Buy |
10,942
+9,788
| +848% | +$163K | ﹤0.01% | 11069 |
|
|
2022
Q4 | $17.7K | Sell |
1,154
-109
| -9% | -$1.27K | ﹤0.01% | 11802 |
|
|
2022
Q3 | $8K | Sell |
1,263
-1,031
| -45% | -$8.62K | ﹤0.01% | 12827 |
|
|
2022
Q2 | $21K | Buy |
+2,294
| New | +$40.8K | ﹤0.01% | 12361 |
|
|
2021
Q4 | – | Sell |
-1,793
| Closed | -$124K | – | 14224 |
|
|
2021
Q3 | $165K | Sell |
1,793
-240
| -12% | -$19.9K | ﹤0.01% | 11708 |
|
|
2021
Q2 | $194K | Sell |
2,033
-2,399
| -54% | -$210K | ﹤0.01% | 11633 |
|
|
2021
Q1 | $432K | Buy |
4,432
+3,188
| +256% | +$392K | ﹤0.01% | 9814 |
|
|
2020
Q4 | $103K | Buy |
+1,244
| New | +$114K | ﹤0.01% | 10480 |
|
|
2020
Q3 | – | Sell |
-4,723
| Closed | -$356K | – | 11342 |
|
|
2020
Q2 | $416K | Sell |
4,723
-782
| -14% | -$82.7K | ﹤0.01% | 7759 |
|
|
2020
Q1 | $616K | Buy |
+5,505
| New | +$1.08M | ﹤0.01% | 6478 |
|
|
2019
Q4 | – | Sell |
-191
| Closed | -$48.2K | – | 10920 |
|
|
2019
Q3 | $66K | Sell |
191
-388
| -67% | -$211K | ﹤0.01% | 9705 |
|
|
2019
Q2 | $533K | Buy |
+579
| New | +$711K | ﹤0.01% | 7131 |
|
|
2019
Q1 | – | Sell |
-258
| Closed | -$465K | – | 10127 |
|
|
2018
Q4 | $482K | Sell |
258
-291
| -53% | -$633K | ﹤0.01% | 6113 |
|
|
2018
Q3 | $1.29M | Buy |
+549
| New | +$1.7M | ﹤0.01% | 4750 |
|
|
2017
Q1 | – | Sell |
-862
| Closed | -$2.48M | – | 10259 |
|
|
2016
Q4 | $1.95M | Buy |
+862
| New | +$2.05M | ﹤0.01% | 4123 |
|
|
2016
Q2 | – | Sell |
-412
| Closed | -$1.34M | – | 9526 |
|
|
2016
Q1 | $1.31M | Buy |
412
+352
| +587% | +$1.46M | ﹤0.01% | 4546 |
|
|
2015
Q4 | $308K | Sell |
60
-191
| -76% | -$835K | ﹤0.01% | 7650 |
|
|
2015
Q3 | $798K | Buy |
251
+138
| +122% | +$535K | ﹤0.01% | 6210 |
|
|
2015
Q2 | $453K | Sell |
113
-168
| -60% | -$649K | ﹤0.01% | 7817 |
|
|
2015
Q1 | $1.12M | Buy |
281
+143
| +104% | +$655K | ﹤0.01% | 5513 |
|
|
2014
Q4 | $675K | Sell |
138
-28
| -17% | -$120K | ﹤0.01% | 6643 |
|
|
2014
Q3 | $673K | Sell |
166
-204
| -55% | -$765K | ﹤0.01% | 6664 |
|
|
2014
Q2 | $1.5M | Sell |
370
-52
| -12% | -$212K | ﹤0.01% | 5234 |
|
|
2014
Q1 | $1.92M | Buy |
422
+91
| +27% | +$368K | ﹤0.01% | 4423 |
|
|
2013
Q4 | $1.16M | Buy |
331
+276
| +502% | +$1.08M | ﹤0.01% | 5244 |
|
|
2013
Q3 | $226K | Sell |
55
-95
| -63% | -$409K | ﹤0.01% | 7592 |
|
|
2013
Q2 | $594K | Buy |
+150
| New | +$618K | ﹤0.01% | 5794 |
|
Other funds holding ACOR
DKCM
Susquehanna International Group's ACOR Position: Q2 2023 in Review
Susquehanna International Group sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 10,942 shares — an estimated $128K sold.
Susquehanna International Group first reported a position in ACOR in Q2 2013 and held it in 27 quarters. The position peaked at $1.95M in Q4 2016. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.
- Susquehanna International Group reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
- Susquehanna International Group sold 10,942 Acorda Therapeutics shares in Q2 2023, an estimated $128K.
- Susquehanna International Group first reported a position in Acorda Therapeutics in Q2 2013 and held it in 27 quarters.
- Susquehanna International Group's Acorda Therapeutics position peaked at $1.95M in Q4 2016.
- 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.